(Q34928086)

5 August 2017

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. (English)

1 reference

5 August 2017

1 reference

K Shiva Kumar

1

1 reference

5 August 2017

Mark W Russo

2

1 reference

5 August 2017

Alain C Borczuk

3

1 reference

5 August 2017

Melissa Brown

4

1 reference

5 August 2017

Stephen P Esposito

5

1 reference

5 August 2017

Steven J Lobritto

6

1 reference

5 August 2017

Ira M Jacobson

7

1 reference

5 August 2017

Robert S Brown

8

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

The American Journal of Gastroenterology

5 August 2017

1 reference

5 August 2017

97

1 reference

5 August 2017

9

1 reference

5 August 2017

2432-2440

1 reference

Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis

5 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

Cryptogenic organizing pneumonia. A report of 25 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

Organizing pneumonia. Features and prognosis of cryptogenic, secondary, and focal variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

Sarcoidosis and IFN-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2002.05999.X

10.1111/J.1572-0241.2002.05999.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference